Sun-Hong Kwon

Dr. Sun-Hong Kwon


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2022 in JAMA Ophthalmology
Verified
Journal Article
Open access
PDF file
JCJeong-Yeon Cho
Jeong-Yeon Cho
YWYeo Kyoung Won
Yeo Kyoung Won
JPJongyeop Park
Jongyeop Park
JNJin Hyun Nam
Jin Hyun Nam
JHJi-Yoon Hong
Ji-Yoon Hong
DLDONG HUI LIM
DONG HUI LIM
In recent years, various types of presbyopia-correcting intraocular lenses (IOLs) have been developed to achieve clear intermediate and near visual acuity without glasses following cataract surgery. These include conventional multifocal (bifocal, trifocal, quadrifocal), accommodative, and extended depth-of-focus (EDOF) IOLs.1-5 In contrast to the standard monofocal IOLs that provide patients with good visual acuity at 1 focal point,1 multifocal IOLs can produce more than 1 focus based on refractive or diffractive optics, thereby affording adequate far and near vision.4 Thus, they minimize spectacle dependency after cataract surgery. However, patients may experience difficulties, such as reduced contrast sensitivity, glare, halos, or blurred vision, which may stem from the structural principles of multifocal IOLs.2

28 January 2014 in Archives of Pharmacal Research
Verified
Journal Article
Closed access
PDF file
HKHye-Lin Kim
Hye-Lin Kim
MLMin-Young Lee
Min-Young Lee
SPSun-Young Park
Sun-Young Park
SPSun-Kyeong Park
Sun-Kyeong Park
JBJi-Hye Byun
Ji-Hye Byun
Eui-Kyung LeeEui-Kyung Lee
Eui-Kyung Lee

1 March 2017 in Clinical Therapeutics
Verified
Journal Article
Closed access
YLYoo Ju Lee
Yoo Ju Lee
SKSun-Hong Kwon
Sun-Hong Kwon
SHSung-Hyun Hong
Sung-Hyun Hong
JNJin Hyun Nam
Jin Hyun Nam
HSHyun Jin Song
Hyun Jin Song
JSJu-Young Shin
Ju-Young Shin

3 January 2017 in Expert Review of Pharmacoeconomics & Outcomes Research
Verified
Journal Article
Closed access
SKSun-Hong Kwon
Sun-Hong Kwon
SPSun-Kyeong Park
Sun-Kyeong Park
JBJi-Hye Byun
Ji-Hye Byun
Eui-Kyung LeeEui-Kyung Lee
Eui-Kyung Lee
Introduction: In order to look beyond the cost-effectiveness analysis, this study used a multi-criteria decision analysis (MCDA), which reflects societal values with regard to reimbursement decisions. This study aims to elicit societal preferences of the reimbursement decision criteria for anti cancer drugs from public and healthcare professionals. Methods: Eight criteria were defined based on a literature review and focus group sessions: disease severity, disease population size, pediatrics targets, unmet needs, innovation, clinical benefits, cost-effectiveness, and budget impacts. Using quota sampling and purposive sampling, 300 participants from the Korean public and 30 healthcare professionals were selected for the survey. Preferences were elicited using an analytic hierarchy process. Results: Both groups rated clinical benefits the highest, followed by cost-effectiveness and disease severity, but differed with regard to disease population size and unmet needs. Innovation was the least preferred criteria. Conclusions: Clinical benefits and other social values should be reflected appropriately with cost-effectiveness in healthcare coverage. MCDA can be used to assess decision priorities for complicated health policy decisions, including reimbursement decisions. It is a promising method for making logical and transparent drug reimbursement decisions that consider a broad range of factors, which are perceived as important by relevant stakeholders.

13 December 2021 in Frontiers in Pharmacology
Verified
Journal Article
Open access
JBJoo-Young Byun
Joo-Young Byun
HKHye-Lin Kim
Hye-Lin Kim
Eui-Kyung LeeEui-Kyung Lee
Eui-Kyung Lee
SKSun-Hong Kwon
Sun-Hong Kwon
Background: The disease burden of active tuberculosis (TB) is considerable, but systematic reviews of economic evaluations of active TB treatments are scarce.Methods: PubMed, EMBASE, and the Cochrane Library databases were used to search for articles on cost-effectiveness analysis or cost-utility analysis that economically evaluated active TB treatments, which were then systematically reviewed by two independent reviewers. We extracted vital components of the included studies, such as country, population, intervention/comparator, primary outcome, values of outcomes, thresholds, model type, time horizon, and health states included in the model.Results: Seventeen studies were included in this systematic review. Thirteen dealt with interventions of medications, and the remaining four compared care strategies. The Markov model was the most commonly used tool to compare medications, whereas studies on care plans mainly used decision trees. The most commonly used primary outcome was disability-adjusted life years, followed by quality-adjusted life years. For treatment-naïve TB, the 4-month regimen was more cost-effective than the 6-month regimen mainly in low- and middle-income countries. For multidrug-resistant TB, a bedaquiline-based regimen was cost-effective. For multidrug-resistant TB, decentralized care that employed the use of home or mobile devices was more cost-effective than hospital-based centralized care in low- and middle-income countries.Conclusion: New treatment strategies to improve therapeutic outcomes by enhancing treatment adherence, such as regimens with shorter durations (2 or 4 months) and decentralized care, or new anti-TB agents (e.g., bedaquiline) have been suggested as cost-effective interventions for active TB. This review provides information on the economic evaluation of active TB from good-quality studies, thus aiding the future economic evaluation of active TB.

15 July 2022 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
SJSuk-Chan Jang
Suk-Chan Jang
JNJin Hyun Nam
Jin Hyun Nam
SLSeung-Ah Lee
Seung-Ah Lee
DADasom An
Dasom An
HKHye-Lin Kim
Hye-Lin Kim
Eui-Kyung LeeEui-Kyung Lee
Eui-Kyung Lee
Background: Transthyretin cardiac amyloidosis, also known as transthyretin cardiomyopathy (ATTR-CM) is a poorly-recognized disease with delayed diagnosis and poor prognosis. This nationwide population-based study aimed to identify disease manifestations, economic burden, and mortality of patients with ATTR-CM. Methods: Data of newly diagnosed patients with ATTR-CM between 2013 and 2018 from the Korean National Health Insurance Service were used, covering the entire population. Patient characteristics included comorbidities, medical procedures, and medication. Healthcare resource utilization and medical costs were observed as measures of the economic burden. The Kaplan–Meier survival curve and years of potential life lost (YPLL) from the general population were estimated for disease burden with ATTR CM. Results: A total of 175 newly diagnosed patients with ATTR-CM were identified. The most common cardiac manifestation was hypertension (51.3%), while the most common non-cardiac manifestation was musculoskeletal disease (68.0%). Mean medical costs at the post-cohort entry date were significantly higher than those at the pre-cohort entry date ($1,864 vs. $400 per patient per month (PPPM), p < 0.001). Of the total medical costs during the study period, the proportion of inpatients cost was 12.9 times higher than the outpatients cost ($1,730 and $134 PPPM, respectively). The median survival time was 3.53 years from the first diagnosis of ATTR-CM, and the mean (SD) YPLL was 13.0 (7.7). Conclusions: Patients with ATTR-CM had short survival and high medical costs. To reduce the clinical and economic burdens, carefully examining manifestations of disease in patients can help with early diagnosis and treatment.